GlassScriptPhysician profile
Elizabeth Piazza Chase
NPI 1811256530
$2,175.27
in general payments reported to CMS, 2019-2025
19 companies · $1,211 in 2025
The $1,211 reported for 2025 was more than what 79% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $200 · 2022: $38.23 · 2023: $192 · 2024: $212 · 2025: $1,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,615.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $635.98 | 2019-2025 | Rinvoq |
| Sun Pharmaceutical Industries INC. | $373.35 | 2022-2025 | |
| Leo Pharma INC. | $216.22 | 2019-2025 | Adbry, Anzupgo |
| Incyte Corporation | $138.64 | 2025 | Opzelura, Opzelura |
| Regeneron Healthcare Solutions, INC. | $137.22 | 2019-2023 | Libtayo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $132.07 | 2020-2025 | Jublia, Cabtreo, Siliq |
| Lilly USA, LLC | $111.49 | 2019-2025 | Ebglyss, Taltz |
| Janssen Biotech, INC. | $99.99 | 2020 | |
| Galderma Laboratories, L.P. | $71.71 | 2019 | |
| Pfizer INC. | $48.90 | 2023-2025 | |
| Organogenesis INC. | $46.55 | 2025 | Affinity |
| Amgen INC. | $38.34 | 2024-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $38.09 | 2023-2024 | Vtama |
| Organon LLC | $20.52 | 2025 | |
| Botanix Sb INC | $19.74 | 2025 | Sofdra |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $18.72 | 2019 | |
| Verrica Pharmaceuticals INC. | $13.51 | 2025 | Ycanth |
| Mission Pharmacal Company | $11.08 | 2019 | |
| Mayne Pharma Commercial LLC | $3.15 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Chase listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.